Johnson & Johnson and Sanofi's vaccine for preventing invasive disease caused by the problem pathogen Escherichia coli looks all but defunct after the two partners halted a phase 3 trial. In a ...
Subscribe to our weekly newsletter for the latest in industry news, expert insights, dedicated information security content and online events.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results